Clinical trial
An Open-Label, Randomized Phase II Study of Becotatug Vedotin With or Without PD-1 Inhibitor Immunotherapy in Patients With Advanced Esophageal Squamous Cell Carcinoma Refractory to Previous Immunochemotherapy
NCT07403136 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Randomized Phase II Study of Becotatug Vedotin With or Without PD-1 Inhibitor Immunotherapy in Patients With Advanced Esophageal Squamous Cell Carcinoma Refractory to Previous Immunochemotherapy
- Lead sponsor
- Fudan University
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- April 30, 2026
- Completion date
- January 31, 2029
- Enrollment
- 104 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.